Company / Return on Equity (ROE)
FENNEC PHARMACEUTICALS INC. Return on Equity (ROE) History
FY2015-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-62.3%
FY2021
5-year range
-62.3% / -46.4%
FY2017-FY2021
Trend
-34.3%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
FENNEC PHARMACEUTICALS INC. reports negative total equity of -62.3% in FY2021. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-62.3% in FY2021 with a 5-year CAGR of +58.0%.
Declined from -26.3% to -62.3% over the past 3 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -36.0pp
- 5-Year Change
- +58.0pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2021, return on equity (roe) decreased 34.3% year-over-year.
- Peak return on equity (roe) was recorded in FY2018.
- Lowest return on equity (roe) in the period was in FY2015.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2021 | -62.3% | -34.3% |
| FY2019 | -46.4% | -76.2% |
| FY2018 | -26.3% | +66.3% |
| FY2017 | -78.1% | +35.0% |
| FY2016 | -120.3% | +66.1% |
| FY2015 | -355.0% | - |
| FY2014 | - | - |
As of FY2021 · SEC 10-K Annual Filings · Updated Jun 24, 2026